For Healthcare Professionals

Podcasts And Expert Series

Clot, Clot, Who's There?

Explore the world of thrombosis and hemostasis with "Clot Clot, Who's There?", a thought-provoking podcast brought to you by Vasculearn Network in collaboration with the Thrombosis and Haemostasis Editors (Thieme).

Explore the world of thrombosis and hemostasis with "Clot Clot, Who's There?", a thought-provoking podcast brought to you by Vasculearn Network in collaboration with the Thrombosis and Haemostasis Editors (Thieme).

Explore the world of thrombosis and hemostasis with "Clot Clot, Who's There?", a thought-provoking podcast brought to you by Vasculearn Network in collaboration with the Thrombosis and Haemostasis Editors (Thieme).

Inside the Lab: Bypassing Factor Xa Inhibitors

Stopping the Second Stroke: Emerging Strategies in Secondary Prevention

Precision Over Prescription: Antithrombotic Therapy and CAD

AF Gone, Clot Still Knocking?

What's Clotting in 2026

A Bridge Too Far? Navigating Perioperative Anticoagulation Challenges in Nonurgent Procedures

Smarter, Safer Antithrombotic Care: What Stewardship Really Means

Recent Advances in Immunothrombosis & Thromboinflammation

When Time is Limb: Acute Limb Ischemia and Thrombotic Emergencies

Conversations That Count: Communicating With Patients About Anticoagulation

Global Rhythm: US and European Atrial Fibrillation Guidelines Head-to-Head

Risky Business: Stratifying VTE and Managing Anticoagulation

Sex as a Risk Factor for AF-related Stroke

The Burden of Atrial Fibrillation

Cholesterol Conversations: Special Edition VLN Podcast

Cholesterol Conversations: Special Edition VLN Podcast

Statins are the first-line therapy for lowering LDL-C and reducing ASCVD risk, yet many high-risk patients remain undertreated. VLN’s Cholesterol Conversations podcast explores the latest ASCVD management guidance, treatment options for optimal LDL-C lowering, and emerging data on novel and combination therapies.

Statins are the first-line therapy for lowering LDL-C and reducing ASCVD risk, yet many high-risk patients remain undertreated. VLN’s Cholesterol Conversations podcast explores the latest ASCVD management guidance, treatment options for optimal LDL-C lowering, and emerging data on novel and combination therapies.

Statins are the first-line therapy for lowering LDL-C and reducing ASCVD risk, yet many high-risk patients remain undertreated. VLN’s Cholesterol Conversations podcast explores the latest ASCVD management guidance, treatment options for optimal LDL-C lowering, and emerging data on novel and combination therapies.

Follow Along & Subscribe to VLN's Channel:
Mastering LDL Management in 2025

Mar 30, 2025

How Do We Get There from Here: Partnering with Patients to Achieve LDL Goals

Mar 8, 2023

ASCVD Management: Making the Case for Nonstatin Therapies

Feb 21, 2023